載入中
Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-24-hour sleep-wake disorders, and Fanapt oral tablets, used in the management of schizophrenia. Vanda maintains an active and diverse development pipeline, exploring new applications for its existing therapies and advancing a range of novel compounds. This includes expanding HETLIOZ (tasimelteon) to potentially treat conditions such as jet lag disorder, Smith-Magenis Syndrome, pediatric Non-24, autism spectrum disorder, and delayed sleep phase disorder. Fanapt (iloperidone) is being investigated for bipolar disorder, alongside the creation of a long-acting injectable formulation for schizophrenia. Other promising candidates in development include: Tradipitant (VLY-686): A small molecule neurokinin-1 receptor (NK-1R) antagonist for atopic dermatitis, gastroparesis, and motion sickness. VTR-297: A small molecule histone deacetylase inhibitor, primarily for hematologic malignancies but with broader oncology potential. VQW-765: A small molecule nicotinic acetylcholine receptor partial agonist targeting psychiatric disorders. A portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) activators and inhibitors aimed at dry eye and ocular inflammation. BPO-27: For secretory diarrhea disorders, including cholera. VHX-896: The active metabolite of iloperidone. Vanda Pharmaceuticals Inc. markets its products in the United States, Europe, and Israel. The company was established in 2002 and is headquartered in Washington, D.C.
一般交易時段
US$4.425
−US$0.115 · -2.53%
盤中時間採用ET。市場資料可能有所延遲。
Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-24-hour sleep-wake disorders, and Fanapt oral tablets, used in the management of schizophrenia. Vanda maintains an active and diverse development pipeline, exploring new applications for its existing therapies and advancing a range of novel compounds. This includes expanding HETLIOZ (tasimelteon) to potentially treat conditions such as jet lag disorder, Smith-Magenis Syndrome, pediatric Non-24, autism spectrum disorder, and delayed sleep phase disorder. Fanapt (iloperidone) is being investigated for bipolar disorder, alongside the creation of a long-acting injectable formulation for schizophrenia. Other promising candidates in development include: Tradipitant (VLY-686): A small molecule neurokinin-1 receptor (NK-1R) antagonist for atopic dermatitis, gastroparesis, and motion sickness. VTR-297: A small molecule histone deacetylase inhibitor, primarily for hematologic malignancies but with broader oncology potential. VQW-765: A small molecule nicotinic acetylcholine receptor partial agonist targeting psychiatric disorders. A portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) activators and inhibitors aimed at dry eye and ocular inflammation. BPO-27: For secretory diarrhea disorders, including cholera. VHX-896: The active metabolite of iloperidone. Vanda Pharmaceuticals Inc. markets its products in the United States, Europe, and Israel. The company was established in 2002 and is headquartered in Washington, D.C.
日內區間
目前US$4.425
52週區間
目前US$4.425
盤中時間採用ET。市場資料可能有所延遲。
Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-24-hour sleep-wake disorders, and Fanapt oral tablets, used in the management of schizophrenia. Vanda maintains an active and diverse development pipeline, exploring new applications for its existing therapies and advancing a range of novel compounds. This includes expanding HETLIOZ (tasimelteon) to potentially treat conditions such as jet lag disorder, Smith-Magenis Syndrome, pediatric Non-24, autism spectrum disorder, and delayed sleep phase disorder. Fanapt (iloperidone) is being investigated for bipolar disorder, alongside the creation of a long-acting injectable formulation for schizophrenia. Other promising candidates in development include: Tradipitant (VLY-686): A small molecule neurokinin-1 receptor (NK-1R) antagonist for atopic dermatitis, gastroparesis, and motion sickness. VTR-297: A small molecule histone deacetylase inhibitor, primarily for hematologic malignancies but with broader oncology potential. VQW-765: A small molecule nicotinic acetylcholine receptor partial agonist targeting psychiatric disorders. A portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) activators and inhibitors aimed at dry eye and ocular inflammation. BPO-27: For secretory diarrhea disorders, including cholera. VHX-896: The active metabolite of iloperidone. Vanda Pharmaceuticals Inc. markets its products in the United States, Europe, and Israel. The company was established in 2002 and is headquartered in Washington, D.C.
日內區間
目前US$4.425
52週區間
目前US$4.425
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 2.16億 USD | 1.99億 USD | 1.93億 USD | 2.54億 USD | 2.69億 USD |
| 銷貨成本 | 1304.4萬 USD | 1131.4萬 USD | 1479.6萬 USD | 2428.2萬 USD | 2562.9萬 USD |
| 毛利 | 2.03億 USD | 1.87億 USD | 1.78億 USD | 2.3億 USD | 2.43億 USD |
| 研究與開發 | 1.09億 USD | 7443.1萬 USD | 7682.3萬 USD | 8577萬 USD | 7536.3萬 USD |
| 銷售、一般及管理費用 | 2.38億 USD | 1.46億 USD | 1.13億 USD | 1.36億 USD | 1.24億 USD |
| 營業費用 | 3.54億 USD | 2.28億 USD | 1.92億 USD | 2.24億 USD | 2.01億 USD |
| 利息收入 | — | — | — | — | 19.9萬 USD |
| 折舊和攤銷 | 1191.7萬 USD | 813.2萬 USD | 301萬 USD | 273.3萬 USD | 284.1萬 USD |
| 營業利益 | −1.51億 USD | −4066萬 USD | −1395.2萬 USD | 632.9萬 USD | 4216.5萬 USD |
| 淨利 | −2.2億 USD | −1890萬 USD | 250.9萬 USD | 627.5萬 USD | 3315.2萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$15.50
上漲空間 250.28%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI951.39萬0.00%2.3兆 USD0.03%US$381.73+0.04%
State Street SPDR S&P Biotech ETFXBI804.82萬0.08%103.03億 USD0.35%US$148.69-1.79%
iShares Russell 2000 ETFIWM634.33萬0.01%787.4億 USD0.19%US$277.77-0.05%
Vanguard Extended Market ETFVXF386.17萬0.00%954億 USD0.05%US$233.46-0.03%
iShares Russell 2000 Value ETFIWN232.88萬0.02%137.49億 USD0.24%US$211.52+0.20%
Dimensional - US Small Cap ETFDFAS208.78萬0.01%338.04億 USD0.31%US$78.425+0.33%
iShares Biotechnology ETFIBB201.66萬0.02%108.2億 USD0.44%US$201.5-1.35%
U.S. Small Cap Value Portfolio ETF Class SharesDFSV181.57萬0.01%268.33億 USD0.33%US$38.20+0.58%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Value ETFIWNDimensional - US Small Cap ETFDFASiShares Biotechnology ETFIBBU.S. Small Cap Value Portfolio ETF Class SharesDFSVAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
